Overview A Phase 1/2 Trial of ADI-270 in ccRCC Status: ACTIVE_NOT_RECRUITING Trial end date: 2027-06-01 Target enrollment: Participant gender: Summary This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.Phase: PHASE1 Details Lead Sponsor: Adicet TherapeuticsTreatments: Cyclophosphamidefludarabine